Concurrent hyperfractionated chemoradiotherapy for head and neck squamous cell carcinoma: the prognostic impact of the overall treatment time and completion rates of chemotherapy

SpringerPlus

Table 2 The results of the univariate analyses of factors predicting the survival rates

	n	Local control		Disease-free survival		Distant metastasis-free survival		Overall survival
	n	3-year (%)	p	3-year (%)	p	3-year (%)	p	3-year (%)	p
Age (years)			0.41		0.44		0.81		0.82
<65	33	72		67		87		79
≥65	36	62		59		91		70
PS			0.73		0.63		0.83		0.34
0–1	59	68		64		87		77
2–3	10	64		58		100		61
Clinical stage			0.007		0.0009		0.01		<0.0001
I–II	35	84		84				100
III–IV	34	50		39				49
Tumor stage			<0.0001		<0.0001		0.17		<0.0001
T1–2	55	79		74		80		87
T3–4	14	23		17		90		34
N stage			0.05		0.0091		0.01		0.0012
N0	38	77		77		97		94
N1–3	31	54		43		76		52
Overall treatment (days)			0.039		0.015		0.11		0.02
≤48	45	78		74		91		84
≥49	24	48		41		85		56
Days of RT without carboplatin			0.69		0.61		0.82		0.21
≤5	40	68		64		83		80
≥6	29	64		41		95		67
Hemoglobin at the start of RT (g/dl)			0.30		0.22		0.66		0.02
<12	18	51		44		83		57
≥12	51	71		68		92		82